75 patents
Utility
MASP-2 and MASP-3 Inhibitors, and Related Compositions and Methods, for Treatment of Sickle Cell Disease
28 Dec 23
The present disclosure relates to the use of MASP-2 inhibitors and/or MASP-3 inhibitors and compositions comprising the same for treatment of sickle cell disease, including treatment, reduction, and/or prevention of sickle cell disease symptoms or manifestations.
John D. Belcher, William Jason Cummings, Thomas A. Dudler, Gregory M. Vercellotti
Filed: 9 Mar 23
Utility
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
7 Dec 23
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject.
Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
Filed: 10 Jan 23
Utility
MASP-2 inhibitors and methods of use
7 Nov 23
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
Michael Cicirelli, Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
Filed: 4 Dec 20
Utility
Inhibitors of GPR174 and Uses Thereof
12 Oct 23
GPR174 is an orphan receptor that has been implicated in cancer, nervous system diseases and disorders and neuroregeneration.
Michael Cicirelli, Neil S. Cutshall, Gregory A. Demopulos, George A. Gaitanaris, Alexander Gragerov, Thomas L. Little, Rene Onrust
Filed: 11 Oct 22
Utility
Chimeric Inhibitor Molecules of Complement Activation
21 Sep 23
The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases.
Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
Filed: 9 Aug 22
Utility
Methods and Compositions for Treating Cancer
14 Sep 23
Compounds, compositions, and methods for generating T cells with altered phenotype are disclosed.
George A. Gaitanaris, Marc A. Gavin, Robert H. Lemus, Caglar Cekic, Mohammed Oukka, Trupti Vardam-Kaur
Filed: 12 Sep 22
Utility
Highly Concentrated Low Viscosity MASP-2 Inhibitory Antibody Formulations, Kits, and Methods
20 Jul 23
The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
Filed: 28 Feb 23
Utility
Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
6 Jul 23
In one aspect, the invention provides compositions and methods for preventing, reducing, and/or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and/or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof.
Gregory A. Demopulos, Thomas Dudler, Bo Nilsson
Filed: 3 Nov 22
Utility
MASP-2 inhibitors and methods of use
30 May 23
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung
Filed: 4 Dec 20
Utility
MASP-2 Inhibitors and Methods of Use
11 May 23
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
Filed: 30 Nov 22
Utility
Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods
18 Apr 23
The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
Filed: 30 Aug 17
Utility
Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors
13 Apr 23
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Gregory A. Demopulos, George A. Gaitanaris, Roberto Ciccocioppo
Filed: 31 Aug 22
Utility
Compositions for inhibiting MASP-2 dependent complement activation
28 Mar 23
The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
Filed: 24 Apr 20
Utility
MASP-2 inhibitors and methods of use
21 Feb 23
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
Filed: 29 May 19
Utility
Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome
13 Dec 22
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA).
Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
Filed: 11 Jul 19
Utility
Treatment of addiction and impulse-control disorders using PDE7 inhibitors
11 Oct 22
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Gregory A. Demopulos, George A. Gaitanaris, Roberto Ciccocioppo
Filed: 14 Nov 18
Utility
Biomarker for Assessing the Risk of Developing Acute COVID-19 and Post-acute COVID-19
29 Sep 22
Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2.
Gregory A. Demopulos, Thomas Dudler, Nicholas James Lynch, Hans-Wilhelm Schwaeble, Kathleen Shaffer, Munehisa Yabuki
Filed: 4 Feb 22
Utility
Chimeric inhibitor molecules of complement activation
27 Sep 22
The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases.
Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
Filed: 16 Jul 20
Utility
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
18 Aug 22
In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation.
Hans-Wilhelm Schwaeble, Gregory A. Demopulos, Thomas Dudler, Patrick Gray
Filed: 11 Oct 21
Utility
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
4 Aug 22
In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation.
Gregory A. Demopulos, Hans-Wilhelm Schwaeble
Filed: 11 Oct 21